Moleculin Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Moleculin Biotech
MBRX Stock  USD 2.62  0.03  1.13%   
Moleculin Biotech financial statements provide useful quarterly and yearly information to potential Moleculin Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Moleculin Biotech financial statements helps investors assess Moleculin Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Moleculin Biotech's valuation are summarized below:
Market Capitalization
8 M
Earnings Share
(12.04)
We have found one hundred twenty available fundamental ratios for Moleculin Biotech, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Moleculin Biotech last-minute market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 27.4 M in 2024, whereas Enterprise Value is likely to drop slightly above 2.3 M in 2024.
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 120.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Moleculin Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets35.4 M38.2 M21.7 M
Slightly volatile
Short and Long Term Debt Total406.4 K574 K400.1 K
Pretty Stable
Other Current Liabilities4.4 M4.2 M1.4 M
Slightly volatile
Total Current Liabilities3.7 M6.8 M2.5 M
Slightly volatile
Accounts Payable1.5 M2.5 M970.9 K
Slightly volatile
Cash22.4 M23.6 M13.7 M
Slightly volatile
Non Current Assets Total11.4 M11.9 M7 M
Slightly volatile
Cash And Short Term Investments22.4 M23.6 M13.7 M
Slightly volatile
Common Stock Total Equity83.3 K79.3 K34.5 K
Slightly volatile
Common Stock Shares Outstanding1.6 M2 M2.1 M
Slightly volatile
Liabilities And Stockholders Equity35.4 M38.2 M21.7 M
Slightly volatile
Non Current Liabilities Total2.9 M5.3 M1.9 M
Slightly volatile
Total Liabilities6.5 M12.1 M4.2 M
Slightly volatile
Short and Long Term Debt298.6 K266.8 K356 K
Slightly volatile
Total Current Assets24 M26.3 M14.7 M
Slightly volatile
Short Term Debt174.4 K100 K292.5 K
Slightly volatile
Common Stock33.6 K33 K22.8 K
Slightly volatile
Other Liabilities3.1 M1.6 M1.6 M
Slightly volatile
Property Plant And Equipment Net512.3 K796 K291.8 K
Slightly volatile
Capital Surpluse48.7 M85.9 M41.5 M
Slightly volatile
Other Current Assets3.3 M3.2 M978.3 K
Slightly volatile
Property Plant And Equipment Gross1.8 M1.7 M478.4 K
Slightly volatile
Intangible Assets12.3 M12.8 M11.3 M
Slightly volatile
Property Plant Equipment412.9 K511.8 K250.6 K
Slightly volatile
Net Invested Capital34.9 M26.1 M25.1 M
Slightly volatile
Net Working Capital25.7 M19.5 M15.5 M
Slightly volatile
Net Receivables104 K99 K52.4 K
Very volatile
Capital Stock31.3 K33 K33.2 K
Pretty Stable
Capital Lease Obligations404.8 K574 K377.1 K
Very volatile
Non Current Liabilities Other220.8 K248.4 K270.5 K
Slightly volatile

Moleculin Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income965.1 K1.2 M938.1 K
Pretty Stable
Depreciation And Amortization120.7 K127 K794.8 K
Slightly volatile
Selling General Administrative6.9 M10 M4.6 M
Slightly volatile
Selling And Marketing Expenses5.9 M11.5 M6.1 M
Slightly volatile
Other Operating Expenses18.2 M29.6 M11.4 M
Slightly volatile
Research Development11.3 M19.5 M7 M
Slightly volatile
Total Operating Expenses18.2 M29.6 M11.4 M
Slightly volatile
Reconciled Depreciation141.9 K124 K78.1 K
Slightly volatile

Moleculin Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation112.9 K127 K72.9 K
Slightly volatile
Capital Expenditures137.6 K124 K91.2 K
Slightly volatile
End Period Cash Flow22.4 M23.6 M13.7 M
Slightly volatile
Stock Based Compensation1.7 M2 M1.1 M
Slightly volatile
Begin Period Cash Flow22 M43.1 M12.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.930.97642.4504
Slightly volatile
Payables Turnover0.07780.05080.0632
Slightly volatile
Cash Per Share11.3211.920416.199
Slightly volatile
Days Payables Outstanding7.6 K7.2 K13.6 K
Slightly volatile
Income Quality0.760.80960.8113
Slightly volatile
Intangibles To Total Assets0.450.29170.5197
Slightly volatile
Net Debt To EBITDA0.940.77871.176
Very volatile
Current Ratio4.693.85523.8396
Slightly volatile
Graham Number63.5566.891116
Very volatile
Capex Per Share0.05960.06280.2544
Very volatile
Interest Debt Per Share5.633.574.9202
Slightly volatile
Debt To Assets0.01970.02086.4189
Slightly volatile
Days Of Payables Outstanding7.6 K7.2 K13.6 K
Slightly volatile
Ebt Per Ebit1.011.00470.9544
Slightly volatile
Quick Ratio4.583.93513.755
Slightly volatile
Net Income Per E B T0.921.090.947
Pretty Stable
Cash Ratio4.383.45563.5887
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00511.0147
Slightly volatile
Debt Ratio0.01970.02086.4189
Slightly volatile

Moleculin Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap27.4 M25.4 M29.1 M
Slightly volatile

Moleculin Fundamental Market Drivers

Cash And Short Term Investments23.6 M

Moleculin Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.4 M
Cost Of Revenue127 K143.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY